Open-label Phase 2 study shows a single 25 mg COMP360 psilocybin dose was well tolerated, with no serious adverse events observed, and indicated both rapid and durable improvement in symptoms from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback